BiotechTube
Home/Pipeline/Opicapone (ONGENTYS)

Opicapone (ONGENTYS)

Parkinson's Disease

MarketedCommercial

Key Facts

Indication
Parkinson's Disease
Phase
Marketed
Status
Commercial
Company
Neurocrine Biosciences

About Neurocrine Biosciences

Neurocrine Biosciences has successfully transitioned from a discovery-focused entity to a fully integrated commercial leader in neuroscience. Its mission is to relieve suffering through brave science, exemplified by the blockbuster success of INGREZZA for tardive dyskinesia and a growing portfolio in movement disorders and endocrinology. The company's strategy leverages deep neurobiological expertise to advance a diversified pipeline, pursue strategic collaborations, and expand the labels of its commercial assets to drive sustainable growth.

View full company profile

Therapeutic Areas

NeurologicalNeuroendocrineNeuropsychiatric

Other Parkinson's Disease Drugs

DrugCompanyPhase
NPT200-11Neuropore TherapiesPhase 1
VXX-301VaxxinityPreclinical
BAN2802BioArcticPhase 1
CNM-Au8ClenePhase 2
hpSC-Derived Neural/Dopaminergic CellsInternational Stem CellPreclinical/Early Clinical
SLS-004Seelos TherapeuticsPreclinical
SLS-007Seelos TherapeuticsPreclinical
Parkinson's Disease ResearchProgenaBiomeResearch
A9 Dopaminergic Neuron TherapyTrailhead BiosystemsPre-clinical
golexanoloneUmecrine CognitionPreclinical
Parkin Activator ProgramProgenraPre-clinical
Not SpecifiedAsceneuronNot Disclosed